Three Medical Journals Publish Papers On La Jolla Pharmaceutical's Lupus Drug Candidate

Apr 11, 2001, 01:00 ET from La Jolla Pharmaceutical Company

    SAN DIEGO, April 11 /PRNewswire/ -- La Jolla Pharmaceutical Company
 (Nasdaq:   LJPC) announces the publication of three papers on the clinical
 development of its lupus drug candidate, LJP 394, in Lupus, Expert Opinion of
 Investigational Drugs, and The Journal of Rheumatology.  The Company is
 currently conducting a Phase III trial designed to confirm the ability of
 LJP 394 to treat lupus kidney disease.
     The first publication, authored by Vibeke Strand, M.D., Biopharmaceutical
 Consultant and Clinical Professor (VCS), Division of Immunology, Stanford
 University School of Medicine, includes a review of recent data on LJP 394.
 The paper, entitled "Monoclonal antibodies and other biologic therapies," is
 included in a special issue of Lupus (volume 10, no. 3, 216-221) published for
 the recently held 6th International Lupus Conference.  Concerning LJP 394
 treatment, Dr. Strand stated that "significant benefit was evident in patients
 with the greatest impairment of renal function pre-treatment."
     In a second publication, Daniel Wallace, M.D., Clinical Professor of
 Medicine, Cedars-Sinai/University of California Los Angeles, summarizes Phase
 I, II, and II/III clinical trial results for LJP 394.  In the article, Dr.
 Wallace said, "LJP 394 represents a unique approach to patients with serious
 lupus.  It appears to be effective and non-toxic."  He added, "Definitive
 trials of LJP 394 for serious lupus are in progress."  The article, published
 in Expert Opinion of Investigational Drugs, volume 10, no. 1, pp 111-117, is
 entitled "Clinical and pharmacological experience with LJP 394."
     A third article, authored by Richard A. Furie M.D., Associate Professor of
 Clinical Medicine at the NYU School of Medicine, discusses the previously
 reported results of a six-month multicenter, placebo-controlled Phase II
 dose-ranging study in 58 patients.  The article, entitled "Treatment of
 systemic lupus erythematosus with LJP 394," was published in The Journal of
 Rheumatology, volume 28, no. 2, pp 257-265.  Dr. Furie concluded, "The
 clinical trial, in which a large number of patients were treated with LJP 394,
 expanded the safety profile of LJP 394 and demonstrated its capacity to reduce
 dsDNA antibodies."
 
     La Jolla Pharmaceutical Company is a biotechnology company developing
 therapeutics for antibody-mediated autoimmune diseases such as lupus, which
 afflict several million people in the United States and Europe.  The Company
 is conducting a Phase III trial of LJP 394 in patients with lupus kidney
 disease, a leading cause of sickness and death in these patients.  The Company
 is also developing drugs for antibody-mediated stroke, heart attack, and
 deep-vein thrombosis, and for other antibody-mediated diseases.  The Company's
 common stock trades on The Nasdaq Stock Market under the symbol LJPC.  For
 more information about the company, visit our website: http://www.ljpc.com.
 
     Except for historical statements, this press release contains
 forward-looking statements, including without limitation statements regarding
 the analysis of results from preclinical and clinical studies as well as La
 Jolla Pharmaceutical's drug candidates and drug development plans.  These
 forward-looking statements involve risks and uncertainties, and a number of
 factors, both foreseen and unforeseen, could cause actual results to differ
 materially from those anticipated.  Clinical results for LJP 394 are derived
 from a trial that was terminated prior to completion, and certain data are
 incomplete.  The Company's blood test to measure binding affinity for LJP 394
 is experimental and has not been validated by independent laboratories.
 Tolerance, or the specific inactivation of pathogenic B cells, is a new
 technology that has not been proven.  The Company's ability to develop and
 sell its products in the future may be affected by the intellectual property
 rights of third parties.  Future clinical trials of the Company's drug
 candidates may have negative or inconclusive results.  Future clinical trials
 of the Company's drug candidates may not support results of preclinical or
 other prior trials and pre IND studies of the Company's new candidate for
 treating antibody-mediated thrombosis may reveal a potential safety issue
 requiring the development of a new candidate.  Any delays in testing of the
 Company's drug candidates and/or termination of development by the Company
 would result in delays or lack of government approval to market the compound.
 The development of drug candidates involves many risks and uncertainties,
 including, without limitation, whether the drug can provide a meaningful
 clinical benefit, and any positive results observed to date may not be
 indicative of future results.  La Jolla Pharmaceutical's other potential drug
 candidates involve comparable risks.  Interested parties are urged to review
 the risks detailed from time to time in La Jolla Pharmaceutical Company's
 Securities and Exchange Commission (SEC) filings, including the report on Form
 10-K for the year ended December 31, 2000.
 
 

SOURCE La Jolla Pharmaceutical Company
    SAN DIEGO, April 11 /PRNewswire/ -- La Jolla Pharmaceutical Company
 (Nasdaq:   LJPC) announces the publication of three papers on the clinical
 development of its lupus drug candidate, LJP 394, in Lupus, Expert Opinion of
 Investigational Drugs, and The Journal of Rheumatology.  The Company is
 currently conducting a Phase III trial designed to confirm the ability of
 LJP 394 to treat lupus kidney disease.
     The first publication, authored by Vibeke Strand, M.D., Biopharmaceutical
 Consultant and Clinical Professor (VCS), Division of Immunology, Stanford
 University School of Medicine, includes a review of recent data on LJP 394.
 The paper, entitled "Monoclonal antibodies and other biologic therapies," is
 included in a special issue of Lupus (volume 10, no. 3, 216-221) published for
 the recently held 6th International Lupus Conference.  Concerning LJP 394
 treatment, Dr. Strand stated that "significant benefit was evident in patients
 with the greatest impairment of renal function pre-treatment."
     In a second publication, Daniel Wallace, M.D., Clinical Professor of
 Medicine, Cedars-Sinai/University of California Los Angeles, summarizes Phase
 I, II, and II/III clinical trial results for LJP 394.  In the article, Dr.
 Wallace said, "LJP 394 represents a unique approach to patients with serious
 lupus.  It appears to be effective and non-toxic."  He added, "Definitive
 trials of LJP 394 for serious lupus are in progress."  The article, published
 in Expert Opinion of Investigational Drugs, volume 10, no. 1, pp 111-117, is
 entitled "Clinical and pharmacological experience with LJP 394."
     A third article, authored by Richard A. Furie M.D., Associate Professor of
 Clinical Medicine at the NYU School of Medicine, discusses the previously
 reported results of a six-month multicenter, placebo-controlled Phase II
 dose-ranging study in 58 patients.  The article, entitled "Treatment of
 systemic lupus erythematosus with LJP 394," was published in The Journal of
 Rheumatology, volume 28, no. 2, pp 257-265.  Dr. Furie concluded, "The
 clinical trial, in which a large number of patients were treated with LJP 394,
 expanded the safety profile of LJP 394 and demonstrated its capacity to reduce
 dsDNA antibodies."
 
     La Jolla Pharmaceutical Company is a biotechnology company developing
 therapeutics for antibody-mediated autoimmune diseases such as lupus, which
 afflict several million people in the United States and Europe.  The Company
 is conducting a Phase III trial of LJP 394 in patients with lupus kidney
 disease, a leading cause of sickness and death in these patients.  The Company
 is also developing drugs for antibody-mediated stroke, heart attack, and
 deep-vein thrombosis, and for other antibody-mediated diseases.  The Company's
 common stock trades on The Nasdaq Stock Market under the symbol LJPC.  For
 more information about the company, visit our website: http://www.ljpc.com.
 
     Except for historical statements, this press release contains
 forward-looking statements, including without limitation statements regarding
 the analysis of results from preclinical and clinical studies as well as La
 Jolla Pharmaceutical's drug candidates and drug development plans.  These
 forward-looking statements involve risks and uncertainties, and a number of
 factors, both foreseen and unforeseen, could cause actual results to differ
 materially from those anticipated.  Clinical results for LJP 394 are derived
 from a trial that was terminated prior to completion, and certain data are
 incomplete.  The Company's blood test to measure binding affinity for LJP 394
 is experimental and has not been validated by independent laboratories.
 Tolerance, or the specific inactivation of pathogenic B cells, is a new
 technology that has not been proven.  The Company's ability to develop and
 sell its products in the future may be affected by the intellectual property
 rights of third parties.  Future clinical trials of the Company's drug
 candidates may have negative or inconclusive results.  Future clinical trials
 of the Company's drug candidates may not support results of preclinical or
 other prior trials and pre IND studies of the Company's new candidate for
 treating antibody-mediated thrombosis may reveal a potential safety issue
 requiring the development of a new candidate.  Any delays in testing of the
 Company's drug candidates and/or termination of development by the Company
 would result in delays or lack of government approval to market the compound.
 The development of drug candidates involves many risks and uncertainties,
 including, without limitation, whether the drug can provide a meaningful
 clinical benefit, and any positive results observed to date may not be
 indicative of future results.  La Jolla Pharmaceutical's other potential drug
 candidates involve comparable risks.  Interested parties are urged to review
 the risks detailed from time to time in La Jolla Pharmaceutical Company's
 Securities and Exchange Commission (SEC) filings, including the report on Form
 10-K for the year ended December 31, 2000.
 
 SOURCE  La Jolla Pharmaceutical Company